Singapore, Aug. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared wi... Read More
Singapore, Aug. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherap... Read More
U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07740239) titled 'A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cO... Read More
U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07739576) titled 'Descriptions and Practices of Family Engagement in Emergency Care Setting' on July 28. Brie... Read More
Singapore, Aug. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Stu... Read More
Singapore, Aug. 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating t... Read More
Singapore, Aug. 1 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Plac... Read More
U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07740122) titled 'AI-Based Stool Image Analysis for Colorectal Neoplasia Risk Assessment' on July 28. Brief S... Read More
Singapore, Aug. 1 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Soluti... Read More
Singapore, Aug. 1 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More